Recent blog posts
Sweet syndrome Indication Strategy Report 2026: IL-1β, Trials and Deals
Latest Hotspot
8 min read
Sweet syndrome Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Sweet syndrome strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Pyoderma gangrenosum Indication Strategy Report 2026: IL-1β, Trials and Deals
Latest Hotspot
8 min read
Pyoderma gangrenosum Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Pyoderma gangrenosum strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Palmoplantar pustulosis Indication Strategy Report 2026: IL-36R, Trials and Deals
Latest Hotspot
8 min read
Palmoplantar pustulosis Indication Strategy Report 2026: IL-36R, Trials and Deals
23 July 2026
2026 Palmoplantar pustulosis strategy: epidemiology, IL-36R biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Generalized pustular psoriasis Indication Strategy Report 2026: IL-36R, Trials and Deals
Latest Hotspot
8 min read
Generalized pustular psoriasis Indication Strategy Report 2026: IL-36R, Trials and Deals
23 July 2026
2026 Generalized pustular psoriasis strategy: epidemiology, IL-36R biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Pityriasis rubra pilaris Indication Strategy Report 2026: IL-17A, Trials and Deals
Latest Hotspot
8 min read
Pityriasis rubra pilaris Indication Strategy Report 2026: IL-17A, Trials and Deals
23 July 2026
2026 Pityriasis rubra pilaris strategy: epidemiology, IL-17A biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Lichen sclerosus Indication Strategy Report 2026: IL-4Rα, Trials and Deals
Latest Hotspot
8 min read
Lichen sclerosus Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Lichen sclerosus strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Lichen planus Indication Strategy Report 2026: JAK1, Trials and Deals
Latest Hotspot
8 min read
Lichen planus Indication Strategy Report 2026: JAK1, Trials and Deals
23 July 2026
2026 Lichen planus strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Allergic contact dermatitis Indication Strategy Report 2026: IL-4Rα, Trials and Deals
Latest Hotspot
8 min read
Allergic contact dermatitis Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Allergic contact dermatitis strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Seborrheic dermatitis Indication Strategy Report 2026: AHR, Trials and Deals
Latest Hotspot
8 min read
Seborrheic dermatitis Indication Strategy Report 2026: AHR, Trials and Deals
23 July 2026
2026 Seborrheic dermatitis strategy: epidemiology, AHR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Dyshidrotic eczema Indication Strategy Report 2026: IL-4Rα, Trials and Deals
Latest Hotspot
8 min read
Dyshidrotic eczema Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Dyshidrotic eczema strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Nummular dermatitis Indication Strategy Report 2026: IL-4Rα, Trials and Deals
Latest Hotspot
8 min read
Nummular dermatitis Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Nummular dermatitis strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
NUT carcinoma Indication Strategy Report 2026: BRD4, Trials and Deals
Latest Hotspot
8 min read
NUT carcinoma Indication Strategy Report 2026: BRD4, Trials and Deals
23 July 2026
2026 NUT carcinoma strategy: epidemiology, BRD4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →